Btn2a2 Regulates ILC2–T Cell Cross Talk in Type 2 Immune Responses.

Bibliographic Details
Title: Btn2a2 Regulates ILC2–T Cell Cross Talk in Type 2 Immune Responses.
Authors: Frech, Michael, Omata, Yasunori, Schmalzl, Angelika, Wirtz, Stefan, Taher, Leila, Schett, Georg, Zaiss, Mario M., Sarter, Kerstin
Source: Frontiers in Immunology; 1/25/2022, Vol. 13, p1-14, 14p
Subject Terms: IMMUNE response, HELMINTHIASIS, T cells, INNATE lymphoid cells, CELLULAR control mechanisms
Abstract: Innate lymphoid cells (ILC) not only are responsible for shaping the innate immune response but also actively modulate T cell responses. However, the molecular processes regulating ILC-T cell interaction are not yet completely understood. The protein butyrophilin 2a2 (Btn2a2), a co-stimulatory molecule first identified on antigen-presenting cells, has a pivotal role in the maintenance of T cell homeostasis, but the main effector cell and the respective ligands remain elusive. We analyzed the role of Btn2a2 in the ILC-T cell cross talk. We found that the expression of Btn2a2 is upregulated in ILC2 following stimulation with IL-33/IL-25/TSLP. In vitro and in vivo experiments indicated that lack of Btn2a2 expression on ILC2 resulted in elevated T cell responses. We observed an enhanced proliferation of T cells as well as increased secretion of the type 2 cytokines IL-4/IL-5/IL-13 following cocultures with Btn2a2-deficient ILC2. In vivo transfer experiments confirmed the regulatory role of Btn2a2 on ILC2 as Btn2a2-deficient ILC2 induced stronger T cell responses and prevented chronic helminth infections. Taken together, we identified Btn2a2 as a significant player in the regulation of ILC2–T cell interactions. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Immunology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:16643224
DOI:10.3389/fimmu.2022.757436
Published in:Frontiers in Immunology
Language:English